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The association between 3020INSC mutation in
NOD2 gene and arterial stiffness in hypertensives
Summary
Background The innate immune system elicits an inflam-
matory process which is believed to be involved in the de-
velopment of vascular damage in hypertension.
The NOD2 gene (CARD15) is involved in the control of
the innate immune system. The aim of this study was to
assess the occurrence of the 3020insC mutation in the
NOD2 gene in relation to vascular damage in
hypertensives.
Materials and methods In 466 hypertensives, genotyping
for 3020insC mutation, cholesterol, serum creatinine, and
echocardiography were carried out. Systolic (SBP) and
diastolic (DBP) blood pressure and pulse pressure (PP)
were taken at 2–3 month intervals for one year and treated
according to ESC/ESH guidelines.
Results The 3020insC mutation was found in 7.08% of
hypertensives and was associated with earlier onset of hy-
pertension 48.2 ± 12.1 vs. 42.8 ± 10.9, p < 0.01 (age of
pts). After one year of treatment, patients with the muta-
tion had significantly higher SBP (138.48 ± 18.35 vs.
131.74 ± 14.97, p < 0.04) and PP (57.27 ± 14.04 vs. 52.70
± 12.96, p < 0.04) than patients without the mutation,
whereas the number of drugs was the same in both groups.
Conclusions The results suggest that the 3020insC muta-
tion is associated with earlier onset of hypertension and
increased arterial stiffness
key words: arterial stiffness, innate immunity, NOD2
mutation
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Introduction
The structural and functional changes of vascular
vessels characterize arterial hypertension. Remodel-
ling of vessels results in thickening of the artery wall,
increased pulse pressure, and atherosclerosis [1, 2].
Many factors are believed to be involved in the deve-
lopment of vascular damage in hypertension, and
recently, innate and adaptive immune mechanisms
are recognized as a cause of atherosclerosis and re-
modelling of vessels [3–6]. The innate immune sys-
tem elicits inflammatory response to various patho-
gens via various receptors [7–9]. The NOD2 gene
(also known as CARD15), discovered in 2001, is be-
lieved to be involved in the control of the innate im-
mune system activating nuclear factor kB and cau-
sing the inflammatory reaction and apoptosis [10–16].
Apoptosis and inflammation play crucial roles in
the process of the of remodelling of arteries in hy-
pertension [17]. Several mutations have been iden-
tified in the NOD2 gene, which are linked to inflam-
mation and apoptosis. One of them, frameshift mu-
tation 3020insC (1007fs), occurs in the European po-
pulation relatively often and has been proven to be
associated with the inflammatory process [18–20]. In
2005 the NOD2 gene was discovered in human en-
dothelium [21, 22]. Recently, it was shown that alle-
lic variants of NOD2 were associated with preec-
lampsia syndrome with susceptibility to severe hy-
pertension [23]. In the face of the relation between
NOD2 mutation and blood pressure control in pre-
eclampsia, it appears very likely that mutation in the
NOD2 gene is associated with vascular vessel func-
tion and structure. We tested only the 1007fs muta-
tion in the NOD2 gene because our previous study
showed that frequency NOD2 gene variants
(1007fs,G908R and R702W and P268S polymor-
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phism) in the Polish population of patients with rec-
tal cancer was found in the 1007fs mutation and the-
re is an association between frequency of cancer and
age [23–25].
The aim of the study was to see whether the oc-
currence of the 3020insC mutation in the NOD2
gene is associated with the clinical manifestation of
cardiovascular damage in hypertensives.
Materials and methods
The study included 466 hypertensives treated in
the Cardiology Outpatient Clinic in Lecznice Cito-
med in Toruń. The study was in accordance with
the Declaration of Helsinki and was approved by the
Commission of Bioethics at Collegium Medicum of
Nicolaus Copernicus University in Toruń. Informed
consent was obtained from all subjects.
The enrolment examination included medical hi-
story, current therapy, previously diagnosed cardio-
vascular diseases, physical examination, and BMI.
Fasting blood was sampled in tubes with EDTA for
genotyping, total cholesterol, and creatinine and sto-
red at –80°C. eGFR was estimated according to
MDRD formula. Total cholesterol was determined
enzymatically, and creatinine according to Jaffe’s
method. Left ventricular mass (LVM) was estimated
using a Vivid 3 GE echocardiograph with a 2.5 MHz
ultrasound probe according to Penn convention and
Devereux formula and expressed as left ventricular
mass index (LVMI) calculated as LVM/body surface
area [16].
Blood pressure measurements (BP) were taken at
2–3 month intervals over one year in accordance with
ESC/ESH 2003 guidelines. The mean of two conse-
cutive measurements were reported. The target blo-
od pressure values were < 140 mm Hg systolic (SBP)
and < 90 mm Hg diastolic (DBP) for nondiabetics.
Pulse pressure (PP) was calculated according to the
equation PP = SDP-DBP. All patients were subjec-
ted to antihypertensive therapy according to ESC/
/ESH guidelines.
Genotyping
The 3020insC mutation was detected using PCR
reaction [4]. For the PCR reaction, four different pri-
mers were used: “3020sens”, “3020anty”, “3020wild”,
and “3020mut”, forming three different pairs. The
“3020wild” and “3020mut” primers have a wild se-
quence and a 1007fs mutation equivalent, respecti-
vely, on their 3’ ends. The thermal conditions of the
PCR reaction and the concentrations of the substra-
tes were adjusted so the highest specificity could be
obtained. If the 3020insC mutation appeared, the
“3020mut” primer bound to the DNA on the tem-
plate while the “3020insC” primer did not. After-
wards, the product of the reaction was subjected to
electrophoresis. An exemplary photogram of electro-
phoresis with marked 3020insC mutation is shown
in figure 1.
Statistical analysis
Statistical analysis was performed with SPSS 12.0
PL software and Microsoft Excel calculation sheet.
The patients included in the study were divided into
two groups: one group consisted of patients with
identified 3020insC mutation in NOD2 (NOD2(+)),
and the second group comprised patients with nega-
tive results (NOD2(–). For each variable, mean va-
lue and standard deviation were calculated using t-
Student or Mann-Whitney test. Shapiro-Wilk test
was used to estimate normality of distribution.
p < 0.05 was considered significant. The ANCOVA
test was applied to compare mean values between
the groups. Linear regression analysis was used to
evaluate the correlation between variables.
Results
3020insC mutation in the NOD2/CARD15 gene
was found in 33 hypertensives (7.08%) (16 females
and 17 males). The NOD2(+) was associated with
earlier onset of hypertension (tab. I), and higher sy-
stolic blood pressure and pulse pressure in the face of
the same number of taken antihypertensive drugs
(tab. II, fig. 2). LVMI and eGFR mean values did
Figure 1. Electrophoretic separation of PCR reaction product.
The 3020insC mutation is marked by arrows. Single arrow —
heterozygote, double arrow — homozygote, K1 — control test:
heterozygote, K2 — control test: homozygote
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not differ significantly in respect to the appearance of
the 3020insC mutation (tab. I). In multivariate ana-
lysis gender, SBP and PP were all predictive of LVMI
(p = 0.00; p = 0.03; p = 0.04, respectively), while
GFR was influenced only by gender (p = 0.02).
None of these parameters appeared to be influenced
by the presence of the 3020insC mutation.
Discussion
This cross-sectional study suggests that the
3020insC mutation in the NOD2/CARD15 gene pre-
disposes to earlier onset of hypertension and worse
blood pressure control. It is known that the frequen-
cy of these mutations is related to some inflammato-
Table I. Clinical characteristics of patients in NOD2(–) and NOD2(+) groups (mean ± SD)
Parameter NOD2(–) NOD2(+) p
n = 433  n = 33
Age (years) 59.4 ± 9.5 56.4 ± 10.4 NS
Onset of hypertension (patient age)  48.2 ± 12.1  42.8 ± 10.9  0.01
BMI [kg/m2] 29.5 ± 4.3 30.00 ± 4.8 NS
Total cholesterol [mg/dl] 223.1 ± 47.6 216.9 ± 48.1 NS
GFR [ml/min/1.73 m2] 86.9 ± 23.5 94.1 ± 27.1 NS
LVMI [g/m2] 117.3 ± 24.5 124.2 ± 28.3 NS
Figure 2. Number of antihypertensive drugs given to NOD2(+) and NOD2(–) patients
Table II. Comparisons of systolic and diastolic blood pressure and pulse pressure among NOD2(–) and NOD2(+)
(mean ± SD) patients
Blood pressure [mm Hg] NOD2(–) NOD2(+) p
SBP 1 151.00 ± 22.12 149.09 ± 22.69 NS
DBP 1 90.25 ± 44.78 91.36 ± 15.68 NS
PP 1 62.39 ± 14.90 57.73 ± 13.41 NS
SBP 2 131.74 ± 14.97 138.48 ± 18.35 0.04
DBP 2 78.90 ± 7.40 81.52 ± 9.40 NS
PP 2 52.70 ± 12.96 57.27 ± 14.04 0.04
SBP — systolic blood pressure, DBP — diastolic blood pressure, PP — pulse pressure, 1 — at the beginning of observation, 2 — after one year of observation
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ry diseases and cancer, but there is no available stu-
dy concerning the relation between the mutation
and the clinical course of hypertension [25–27].
The mechanism/s underlying the association be-
tween NOD2 gene mutation and the pathogenesis
of hypertension is/are still matter of speculation.
NOD2 has been identified as playing a role in inna-
te immune response and consequently initiates the
inflammatory process leading to activation of mo-
nocytes and macrophages. Activated cells bind to
endothelium to initiate the inflammatory process in
vascular vessels, which is associated with reduced
artery compliance [28, 29]. Patients with the
3020insC mutation are characterized with higher
systolic blood pressure and pulse pressure than sub-
jects without mutation. This suggests that the ap-
pearance of the mutation could have been associa-
ted with more advanced inflammatory processes in
the vessels, causing higher vascular stiffness. Our
study also revealed that hypertension was diagno-
sed earlier in subjects with mutation than in sub-
jects without. In several studies, the role of genetic
factors in the early development of hypertension has
been shown [30, 31]. Our findings are in agreement
with a study suggesting a genetic background in the
pathogenesis of hypertension. However, it is diffi-
cult to exclude the role of environmental fator/s
which may be more relevant than the NOD2 muta-
tion. Hence question arises whether mutation
3020insC predisposes to the development of hyper-
tension or not. Taking into account the results of
the previous study on preeclampsia and the role of
innate immunity in vascular damage, it appears
very likely [3–6, 9, 23]. Unfortunately, our study
has not solved this problem. Moreover, our study
has some limitations. Firstly, the sample of subjects
with NOD2 mutation was too small to drawn firm
conclusions. Secondly, we do not know the frequ-
ency of the 3020insC mutation in the population
without hypertension, and in the face of this fact, it
is difficult to prove whether this mutation plays a role
in the pathogenesis of hypertension.
Conclusions
The 3020insC mutation in the NOD2 gene occurs
among hypertensives. It suggests also that the
3020insC mutation may play a role in arterial remo-
delling in hypertensive patients.
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